Cantor Fitzgerald’s Novavax NVAX Stock Holding History

Cantor Fitzgerald’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-21,800	Closed	-$169K	–	281
2024 Q2	$169K	Buy	+21,800	New	+$219K	0.03%	144
2023 Q4	–	Sell	-3,207	Closed	-$1.65M	–	454
2023 Q3	$1.65M	Buy	+3,207	New	+$25.6K	0.04%	238

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cantor Fitzgerald's NVAX Position: Q4 2023 in Review

Cantor Fitzgerald sold out of Novavax (NVAX) in Q4 2023, closing a stake of 524,200 shares — an estimated $3.8M sold.

Cantor Fitzgerald first reported a position in NVAX in Q3 2023 and held it in 1 quarter. The position peaked at $3.8M in Q3 2023. 199 funds tracked by Wall St. Rank hold NVAX as of Q4 2023.

Cantor Fitzgerald reported no remaining Novavax position as of Q4 2023 after selling out during the quarter.
Cantor Fitzgerald sold 524,200 Novavax shares in Q4 2023, an estimated $3.8M.
Cantor Fitzgerald first reported a position in Novavax in Q3 2023 and held it in 1 quarter.
Cantor Fitzgerald's Novavax position peaked at $3.8M in Q3 2023.
199 funds tracked by Wall St. Rank held Novavax as of Q4 2023.

Based on Cantor Fitzgerald's 13F filing for Q4 2023, filed 14 Feb 2024.